TREOSULFAN TILLOMED 5g powder for solution for infusion LABORATORIOS TILLOME
Chemical substance: treosulfan
ATC code: L01AB02 • Antineoplastic and immunomodulating agents | Alkylating agents | Alkyl sulfonates
Active substance
Results for the substance treosulfan
2 results
About this active substance
Treosulfan is an alkylating agent primarily used as part of conditioning regimens for hematopoietic stem cell transplantation. It works by forming covalent bonds with DNA, leading to the inhibition of cellular replication and the destruction of malignant or existing hematopoietic cells.
Treosulfan is administered intravenously, usually in combination with other drugs such as fludarabine, to prepare patients for transplantation. It is particularly used in patients who cannot tolerate more intensive conditioning regimens due to its lower toxicity profile.
Common side effects include myelosuppression, nausea, vomiting, diarrhea, and fatigue. In rare cases, severe adverse reactions such as hepatotoxicity, pulmonary function impairment, or serious infections may occur. Careful monitoring of hematological parameters and organ function is essential during treatment.
Treosulfan is an important therapeutic option for patients requiring stem cell transplantation, contributing to increased success rates and reduced associated risks.
Treosulfan is administered intravenously, usually in combination with other drugs such as fludarabine, to prepare patients for transplantation. It is particularly used in patients who cannot tolerate more intensive conditioning regimens due to its lower toxicity profile.
Common side effects include myelosuppression, nausea, vomiting, diarrhea, and fatigue. In rare cases, severe adverse reactions such as hepatotoxicity, pulmonary function impairment, or serious infections may occur. Careful monitoring of hematological parameters and organ function is essential during treatment.
Treosulfan is an important therapeutic option for patients requiring stem cell transplantation, contributing to increased success rates and reduced associated risks.